Novoste Sees More Beta-Cath Placements, Looks To Exploit First Mover Lead
This article was originally published in The Gray Sheet
Executive Summary
Novoste Corp. expects to place 220-280 Beta-Cath brachytherapy systems in top U.S. centers by the end of 2001, an increase from the company's previous guidance of 180-250 placements for the year.